Big news in the world of biotech sell-side research: Analyst Geoffrey Meacham has left J.P. Morgan ( JPM) and is moving to an expanded research role at Barclays.
Meacham spent 10 years at J.P. Morgan as the bank's lead large-cap biotech analyst. He gave notice to his J.P. Morgan bosses on Friday, he told me in a phone call this morning. The new Barclays gig starts in December. Meacham will take a leadership position building out a full healthcare research team for the London-based investment bank. Meacham will also expand his sell-side coverage to include both biotech and large pharmaceutical stocks.
"I'm really excited about the new job. It's a growth opportunity for me and a chance to start from scratch with a blank state," said Meacham, adding Barclays is committed to investing in healthcare research and banking.
Barclays hasn't had a prominent voice in biotech research since well before the acquisition of the bankrupt Lehman Brothers in 2008. The hiring of the well-liked and respected Meacham gives the investment bank instant credibility.
Meacham will also be swapping venues for healthcare investment conferences. No longer will he be the research "host" of the annual gathering of the biotech tribe at the J.P. Morgan healthcare conference every January. Instead, he'll be welcoming investors to Miami in March, where Barclays holds its annual healthcare investing conference each year.